The extrarenal effects of atrial natriuretic peptide on body fluid distribution. 1990

Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
Second Department of Internal Medicine, University of Tokyo, Japan.

To study the effects of atrial natriuretic peptide (ANP) on body fluid volume regulation, we estimated the changes in intra- and extravascular fluid volume by measuring hematocrit (Hct), plasma protein concentration and water balance, and the changes in intra- and extracellular fluid volume by the electrical impedance method during intravenous infusion of ANP. We did two studies, as follows: ANP was infused into 18 patients with essential hypertension, 29 with renal parenchymal hypertension and 15 normotensives at 0.025 microgram/kg/min for 40 min. Both hypertensive groups showed greater natriuretic responses to ANP than normotensives. ANP infusion into essential hypertensive patients increased the urinary excretion of water by 125%, Na by 205%, Hct by 4.2% and plasma total protein (TP) by 5.2% (each P less than .001). In 9 patients (1 with renal hypertension and 8 normotensives) who did not show a natriuretic response (-2.1%), the infusion of ANP also significantly increased Hct (3.8%) and plasma TP (3.1%, each P less than .01). The electrical impedance method was applied to 12 subjects to simultaneously detect the intracellular (Ri) and extracellular resistivities (Re), of which reciprocals reflect the fluid volume in the extra- and intracellular spaces, respectively. ANP infusion increased Re in all subjects (3.96 +/- 0.16 [SE] v 4.03 +/- 0.16 omega.m, P less than .05), but decreased Ri in 7. Changes in urinary Na excretion correlated positively with those in both Re (r = 0.62, P less than .05) and Ri (r = 0.75, P less than .01).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D007424 Intracellular Fluid The fluid inside CELLS. Fluid, Intracellular,Fluids, Intracellular,Intracellular Fluids
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009318 Natriuresis Sodium excretion by URINATION. Natriureses
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D010953 Plasma Volume Volume of PLASMA in the circulation. It is usually measured by INDICATOR DILUTION TECHNIQUES. Blood Plasma Volume,Blood Plasma Volumes,Plasma Volumes,Volume, Blood Plasma,Volume, Plasma,Volumes, Blood Plasma,Volumes, Plasma
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body

Related Publications

Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
January 1987, Nephrologie,
Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
September 1996, Anaesthesia,
Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
September 1990, Japanese heart journal,
Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
July 1989, Acta physiologica Scandinavica,
Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
October 1989, The Journal of laboratory and clinical medicine,
Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
August 1998, The Journal of thoracic and cardiovascular surgery,
Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
March 1998, The American journal of physiology,
Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
December 1999, Cardiovascular research,
Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
January 1985, Lancet (London, England),
Y Hirata, and M Ishii, and K Fukui, and T Sugimoto, and K Atarashi, and H Matsuoka, and M Iizuka, and T Sugimoto, and K Sakamoto, and H Kanai
December 1998, Canadian journal of physiology and pharmacology,
Copied contents to your clipboard!